Treatable trait guided asthma management: biomarker changes and responder analysis

European Respiratory Journal 2023; 62- Suppl. 67, PA3604.

Aim: In a feasibility study, treatable trait (TT) guided asthma management showed clinically relevant improvements in asthma control (ACQ), quality of life (AQLQ), health status (SGRQ) and FEV1 (Fingleton et al, TSANZ ASM 2023). Changes in two type-2 (T2) biomarkers, blood eosinophils and FeNO, and associations between baseline characteristics and treatment response are described here.

Methods: Ten week two-centre open-label intervention study of patients with asthma receiving medication titrated to presence of two TTs: T2 inflammation and airflow obstruction. Participants had ACQ >1 and ≥1 exacerbation in last 12 months. Linear regression estimates changes in continuous response variables in relation to predictors.

Results: Airflow obstruction was present in 18/30 (60%) participants. Although TT intervention was associated with reduction of type-2 inflammation (Figure); change in ACQ, AQLQ, or SGRQ was not associated with baseline FEV1/FVC, log FeNO, blood eosinophils or composite T2 biomarker status. Final FEV1% predicted, adjusted for baseline, was associated with baseline airflow obstruction. Change in FEV1 predicted per unit increase FEV1/FVC ratio (95% CI), -1.69% (-2.26 to -1.13), P<0.001.

Puedes leer el artículo completo aquí:

Authors: James Fingleton, Rob Mclachlan, Jenny Sparks, Richard Beasley, Alvar Agusti, Peter G Gibson, Ian Pavord, Jo Hardy, Mark Weatherall, Allie Eathorne, Vanessa M Mcdonald
European Respiratory Journal 2023 62: PA3604; DOI: 10.1183/13993003.congress-2023.PA3604

Noticias relacionadas


Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría GOLD en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.

Imagen obtenida en artículo original.